Drugs / CND261
last change Jun 2025 re-read 3 minutes ago

CND261

Developed for
rheumatoid arthritis
Investigated by
Candid Therapeutics

Trials 1

20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07052032 Jun 2025 → Jun 2027 expected rheumatoid arthritis Candid Therapeutics Active not recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CND261 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07052032 ↗